StockData
Moderna, Inc. logo

Moderna, Inc. (MRNA) KPIs and segments

MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30537% above fair value
$196.79−10.01 (-4.84%)

Close on Nov 18, 2026Market cap $78.57BP/E –Yield –

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Moderna · năm tài chính kết thúc Calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q2 2026 ended June 30, 2026)

Nhìn nhanh KPI của Moderna: 30 chỉ số vận hành, trong đó có Net product sales — Total commercial vaccines, Other revenue và Consolidated total revenue by customer geography, lấy từ 93 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Net product sales($M)
94352646973114869381,8201841672,7931,757
COVID($M)
91345642971114849231,8101841672,7931,757
Other revenue($M)
51373243282228425701874
Stand-ready manufacturing revenue($M)
31321712
Collaboration revenue (Note 5)($M)
15517411328702030
Licensing and royalty revenue($M)
302285730000
RSV($M)
37420215100000
Grant revenue($M)
202145110720044
United States($M)
707326478288312491,215162100804913
Europe($M)
1623934160029228100614103
Rest of world($M)
840348175265539732422671,375741
Rentable area1
Cambridge leases(triệu ft²)
0.50.50.50.50.50.70.70.30.3
Net product sales — Total commercial vaccines ($M)($M)3
94352646973114869381,8201841672,7931,757
COVID-19 vaccines (Spikevax / mRNA-1273 & mNEXSPIKE / mRNA-1283) — Net product sales ($M)($M)
91345642971114849231,8101841672,7931,757
Net product sales — United States ($M)($M)
707326478288312491,215162100804913
Approved commercial products on market (products)
4.003.003.003.003.002.002.002.002.00
Other revenue — Stand-ready manufacturing, grants, collaborations & royalties ($M)($M)2
51373243282228425701874
Grant revenue — Total (BARDA, DARPA, CEPI & Gates Foundation) ($M)($M)1
2021451107200-244
BARDA grant revenue (mRNA-1273 & pandemic influenza) ($M)($M)
044
Collaboration revenue — Total ($M)($M)2
15517411328702030
Merck collaboration revenue ($M)($M)
00
AstraZeneca collaboration revenue ($M)($M)
00
Consolidated total revenue by customer geography ($M)($M)
1453896781,0161421089661,8622411672,8111,831
Gross product sales (before gross-to-net variable consideration deductions) ($M)($M)2
1223501,0531,9711761051,1402,9641912223,6622,420
Total gross-to-net (GTN) provisions & variable consideration deductions ($M)($M)4
28-240799862192021,144755869663
GTN provision — Chargebacks, discounts and distribution fees ($M)($M)
50-111917626222881,053-2222497479
GTN provision — Product sales returns ($M)($M)
101411301429
GTN provision related to sales made in current period ($M)($M)
149237175168118
GTN provision adjustment related to sales made in prior periods ($M)($M)
-360-21716114
Actual GTN payments, credits and deductions applied against reserves ($M)($M)1
494994109344226836025511,207282
Actual returns/credits applied related to prior-period sales ($M)($M)
264811910726301332133615
Balance sheet GTN reserves — Refund liability (sales returns & rebates reserve) ($M)($M)4
421470509426308337370403554574556184
Accounts receivable, gross (before chargeback allowances) ($M)($M)
1202033682,0242602496982,7324924221,5842,360
Allowance for chargebacks and cash discounts (contra-AR) ($M)($M)
97126181975212-171340-1,168-329-285-692-479
Allowance for expected credit losses ($M)($M)
66331200
Accounts receivable, net ($M)($M)
17711841,04636783581,5641631378921,866
Deferred revenue — Total customer deposits & Advance Purchase Agreements (APAs) ($M)($M)7
4422562523202831832114747976176511,538
Deferred revenue — Current ($M)($M)
295102991632181251533797025595681,372
Deferred revenue — Non-current ($M)($M)
14715415315765585895955883166
Deferred revenue — Product sales (sovereign APAs & customer deposits) ($M)($M)
265951071442211541884437405806131,493
Deferred revenue — Stand-ready manufacturing, collaborations & grants ($M)($M)
17716114517662292320
Deferred revenue — Collaboration arrangements (legacy disaggregation) ($M)($M)
6733333441
Deferred revenue — Government grants (legacy disaggregation) ($M)($M)
9114444
Revenue recognized from beginning-of-year deferred revenue balance ($M)($M)4
2355326146134145372051732088
Recognized from beginning deferred revenue — Product sales ($M)($M)
17102408401281821430880
Recognized from beginning deferred revenue — Other revenue ($M)($M)
645321465014
Recognized from beginning deferred revenue — Collaborations (legacy) ($M)($M)
5133126
Recognized from beginning deferred revenue — Grants (legacy) ($M)($M)
-180002
Cost of sales — Total ($M)($M)6
9395545220711990739514115969292,241
Cost of sales as % of net product sales (%)(%)
74.0%249.0%21.0%105.0%104.0%79.0%28.0%62.0%58.0%33.0%128.0%
Third-party royalties & milestone payments included in cost of sales ($M)($M)
11895344365459210812578
Inventory write-downs (excess & expiring shelf-life vaccines/raw materials) ($M)($M)
413814467384219321414303001,300
Unutilized manufacturing capacity & CMO wind-down charges ($M)($M)
235221259275527169
Losses on firm purchase commitments & CMO cancellation fees ($M)($M)
000771039210000
Stock-based compensation expense in cost of sales ($M)($M)
1335777666797
Inventory, net — Total on balance sheet ($M)($M)6
280146153332240128117412399295202487
Raw materials inventory ($M)($M)
117949185837563171199215163149
Work in process (drug substance & bulk formulated mRNA) inventory ($M)($M)
973829119112392695166601561
Finished goods (filled & packaged vaccine doses) inventory ($M)($M)
661433128451428146342024277
Gross inventory (including zero-cost raw materials awaiting destruction) ($M)($M)
361263267447367262267477560440372698
Prepaid manufacturing materials & CMO advances, current ($M)($M)
70556177968410619311112316861
Accounts payable — Raw materials & manufacturing suppliers ($M)($M)
442730463028415742362771
Development pipeline — Total active mRNA development programs (programs)2
36.0035.0035.0040.0039.0041.0044.0045.0047.0047.0045.0043.00
Development candidates in pipeline (candidates)
26.0025.0025.0030.0030.0031.0034.0036.0040.0040.0042.0041.00
Development programs currently in clinical studies (programs)
36.0035.0035.0037.0035.0038.0041.0042.0043.0043.0040.0038.00
ClinicalTrials.gov registry — Cumulative Moderna-sponsored studies (studies)9
139.00137.00135.00131.00127.00125.00122.00117.00113.00110.00105.00100.00
Cumulative interventional clinical trials (trials)
116.00114.00112.00108.00104.00102.0099.0094.0090.0087.0083.0078.00
Cumulative Phase 1 clinical trials (trials)
34.0034.0033.0032.0031.0031.0030.0029.0029.0029.0028.0028.00
Cumulative Phase 2 clinical trials (trials)
46.0045.0045.0044.0043.0041.0039.0039.0038.0037.0034.0032.00
Cumulative Phase 3 registrational clinical trials (trials)
34.0033.0032.0030.0028.0028.0028.0025.0022.0020.0020.0017.00
Cumulative respiratory vaccine trials (COVID-19, RSV, Flu, Combo) (trials)
54.0054.0053.0051.0049.0049.0048.0046.0043.0042.0042.0038.00
Cumulative oncology & individualized neoantigen therapy (mRNA-4157) trials (trials)
19.0018.0018.0017.0016.0015.0013.0012.0012.0010.009.008.00
Cumulative latent virus, rare disease & other therapeutic trials (trials)
43.0042.0041.0040.0039.0038.0038.0036.0035.0035.0032.0032.00
Cumulative participant enrollment across interventional clinical trials (participants)1
469,580.00468,338.00464,168.00392,832.00391,288.00390,948.00389,278.00270,934.00190,190.00189,655.00189,381.00178,590.00
Cumulative participant enrollment in Phase 3 registrational trials (participants)
330,807.00329,931.00325,881.00254,821.00253,482.00253,482.00253,482.00249,345.00169,532.00169,269.00169,269.00159,187.00
Newly initiated Moderna clinical studies in period (studies)2
2.002.004.004.002.003.005.004.003.005.005.009.00
Newly initiated interventional clinical trials in period (trials)
2.002.004.004.002.003.005.004.003.004.005.008.00
Target/actual participant enrollment in newly initiated interventional trials (participants)
1,242.004,170.0071,336.001,544.00340.001,670.00118,344.0080,744.00535.00274.0010,791.007,361.00
Research and development expenses — Total GAAP ($M)($M)1
6516497758017008561,1221,1371,2211,0631,4061,160
Stock-based compensation expense in R&D ($M)($M)
646467748169686967604240
Strategic collaborations — Merck (intismeran autogene / mRNA-4157) gross R&D incurred ($M)($M)3
971011031019910411010995766253
Merck (mRNA-4157) 50/50 cost share — Reimbursement recognized as contra-R&D ($M)($M)
1151612272533246816
Collaborative arrangements receivable, current ($M)($M)
011392026589973596144
Research and development partners payable, current ($M)($M)
14043000580
Strategic collaborations — Blackstone Life Sciences (influenza) funding recognized as contra-R&D ($M)($M)2
24506625160902323000
Reimbursement liability to R&D funding partners, current ($M)($M)
581118401181791031190
Upfront licensing & in-process R&D (IPR&D) milestone payments ($M)($M)
11895344365459210812578
Property, plant and equipment, net ($M)($M)4
2,0592,0862,1342,1262,1692,2122,1962,3812,1962,0631,9451,952
Property, plant and equipment, gross ($M)($M)8
2,9082,8802,8712,7972,7922,7782,7232,9322,7002,5282,3783,024
Manufacturing and laboratory equipment, gross ($M)($M)
550543542493433361344384355355345334
Construction in progress (MITC facilities & Norwood expansion), gross ($M)($M)
2792682983509131,0781,057975961865860720
Leasehold improvements, gross ($M)($M)
409408403359264208207674664642522490
Finance lease right-of-use assets, gross ($M)($M)
1321321321321321321326045295295291,367
Buildings and site improvements, gross ($M)($M)
1,2161,2161,1831,160798759743870
Land, gross ($M)($M)
777778785959592222322232
Computer equipment and software, gross ($M)($M)
205196196188161150150153136737455
Furniture and fixtures, gross ($M)($M)
404039373231313333322626
Accumulated depreciation and amortization ($M)($M)
8497947376716235665275515044654331,072
Capital expenditures — Purchases of property and equipment ($M)($M)
376239333117522151182196220140
Non-cash PP&E additions included in accounts payable and accrued liabilities ($M)($M)
13541-5-35019-8-591-1843
Real estate footprint — Leased space in Cambridge, Massachusetts (sq ft)1
462,000.00462,000.00462,000.00462,000.00462,000.00462,000.00462,000.00667,000.00667,000.00276,000.00292,000.00292,000.00
Norwood, Massachusetts manufacturing & technical development campus (sq ft)
722,000.00722,000.00722,000.00722,000.00722,000.00686,000.00686,000.00686,000.00686,000.00686,000.00
Total operating and finance lease liabilities ($M)($M)5
6967087157347417457471,3551,2691,2371,2431,455
Lease liabilities — Current ($M)($M)
5250424843433751252525183
Lease liabilities — Non-current ($M)($M)
6446586736866987027101,3041,2441,2121,2181,272
Operating lease liabilities ($M)($M)
659664670677682682685700693662668730
Finance lease liabilities ($M)($M)
37444557596362655576575575725
Total operating and finance lease right-of-use (ROU) assets ($M)($M)
7277427617858038118241,2821,2051,1301,1491,366
Minimum unconditional purchase obligations — Supply & manufacturing agreements ($M)4
Accrued liabilities — External development & clinical/manufacturing operations ($M)($M)5
7881106941081201208090141140110
Accrued liabilities — Clinical trials ($M)($M)
384620303888945196136175263
Accrued liabilities — Manufacturing ($M)($M)
8679140113152128109137119112167779
Accrued liabilities — Third-party royalties ($M)($M)
954967314265469210812278
Accrued liabilities — Commercial operations ($M)($M)
1816232124244536324056137
Accrued liabilities — Other external goods and services ($M)($M)
588257536382131177109135137145
Accrued liabilities — Employee compensation and benefits ($M)($M)
19210842031019712031224418795245251
Accrued liabilities — Property and equipment ($M)($M)
1831453147499978939594108
Patent infringement & settlement indemnification accrual ($M)($M)1
000000000000
Patent litigation settlement & indemnification expense recognized in period ($M)($M)
000000000000
Available-for-sale (AFS) marketable securities, current — Fair value ($M)($M)9
3,4153,2973,2043,3723,8524,3525,0985,2236,0106,4725,6974,641
Available-for-sale (AFS) marketable securities, non-current — Fair value ($M)($M)
1,7722,2512,3362,1432,3742,4182,4942,3352,3263,6384,6775,273
Cash equivalents & AFS marketable debt securities — Total amortized cost ($M)($M)
5,2025,5565,5335,5106,2276,7757,6147,5778,42910,23210,51910,182
AFS debt securities maturing within 1 year — Fair value ($M)($M)
3,4153,2973,2043,3723,8524,3525,0985,2236,0106,4725,6974,641
AFS debt securities maturing in 1 to 5 years — Fair value ($M)($M)
1,7722,2512,3362,1432,3742,4182,4942,3352,3263,6384,6775,273
Portfolio by asset class — U.S. Treasury & government agency debt securities ($M)($M)
555666307392138152194222208150
Portfolio by asset class — Corporate debt securities & commercial paper ($M)($M)
2,4402,9783,1632,5252,8993,3673,7633,9754,2865,0725,4805,012
Portfolio by asset class — Money market funds ($M)($M)
1,4475959634736495581,1955306477091,5721,438
Portfolio by asset class — Certificates of deposit & time deposits ($M)($M)
53619110390102522729752730
Portfolio by asset class — Marketable equity securities ($M)($M)
226966142331532444
Stock-based compensation (SBC) expense — Total ($M)($M)6
1201041131251301151041121121017977
SBC by award type — Stock options ($M)($M)
292435374139394440403432
SBC by award type — Restricted stock units (RSUs) ($M)($M)
857574848571666667552743
SBC by award type — Performance stock units (PSUs) ($M)($M)
433221-3233
SBC by award type — Employee stock purchase plan (ESPP) ($M)($M)
221224202312
SBC by function — Selling, general and administrative ($M)($M)
433741444239303739342830
Total unrecognized stock-based compensation cost ($M)($M)
8319786337709081,1008208751,0001,200835701
Industry benchmarks (FRED) — U.S. PPI: Pharmaceutical Preparation Manufacturing (Index)3
926.70925.40919.10917.40915.10915.30918.10917.30914.40907.80896.30896.50
U.S. Retail Sales: Pharmacies and Drug Stores, Seasonally Adjusted ($M)($M)
97,48195,519103,201102,234100,19098,46797,36595,99289,71687,92789,67385,816
U.S. Retail Sales: Pharmacies and Drug Stores, Not Seasonally Adjusted ($M)($M)
97,05993,047106,419102,17199,81895,892100,31295,79289,17386,98791,91485,089
U.S. Personal Consumption Expenditures: Health Care Services, SAAR ($B)
3,790.303,699.903,667.003,614.803,529.803,464.703,417.803,358.203,288.203,244.403,159.403,079.00
Income Statement — Total revenue ($M)($M)14
1453896781,0161421089661,8622411672,8111,831
Cost of sales ($M)($M)
9395545220711990739514115969292,241
Research and development expense ($M)($M)
6516497758017008561,1221,1371,2211,0631,4061,160
Selling, general and administrative expense ($M)($M)
216173308268230212351281268274470442
Total operating expenses ($M)($M)
9601,7771,5351,2761,0491,1582,2121,9321,6041,4332,8053,843
Operating income (loss) ($M)($M)
-815-1,388-857-260-907-1,050-1,246-70-1,363-1,2666-2,012
Interest income ($M)($M)
67727073819091103111120103105
Other non-operating income (expense), net ($M)($M)
-19-18-1208-4-29-12-27-19-39-51
Income (loss) before income taxes ($M)($M)
-767-1,334-799-187-818-964-1,18421-1,279-1,16570-1,958
Provision for (benefit from) income taxes ($M)($M)
159271377-648010-1471,672
Net income (loss) ($M)($M)
-782-1,343-826-200-825-971-1,12013-1,279-1,175217-3,630
Earnings (loss) per share — Basic ($/sh)($)
-1.97-3.40-0.51-2.13-2.520.03-3.33-3.07-9.53
Earnings (loss) per share — Diluted ($/sh)($)
-1.97-3.40-0.51-2.13-2.520.03-3.33-3.07-9.53
Weighted-average basic shares outstanding (M)
398.00395.00390.00388.00386.00385.00384.00382.00381.00
Weighted-average diluted shares outstanding (M)
398.00395.00390.00388.00386.00399.00384.00382.00381.00
Balance Sheet — Total assets ($M)($M)27
10,96111,48812,33812,13512,01012,70414,14215,80315,68016,72918,42619,450
Cash and cash equivalents ($M)($M)
1,7231,9082,5951,1321,2791,6231,9291,6442,4782,0512,9072,932
Short-term marketable securities ($M)($M)
3,4153,2973,2043,3723,8524,3525,0985,2236,0106,4725,6974,641
Accounts receivable, net ($M)($M)
17711841,04636783581,5641631378921,866
Inventory, net ($M)($M)
280146153332240128117412399295202487
Prepaid expenses and other current assets ($M)($M)
380348408716764585599823611645627873
Total current assets ($M)($M)
5,8155,7706,5446,5986,1716,7668,0999,6669,6619,60010,32510,799
Long-term marketable securities ($M)($M)
1,7722,2512,3362,1432,3742,4182,4942,3352,3263,6384,6775,273
Property, plant and equipment, net ($M)($M)
2,0592,0862,1342,1262,1692,2122,1962,3812,1962,0631,9451,952
Operating lease right-of-use assets ($M)($M)
697706719738750752759784775697713765
Goodwill ($M)($M)
525252525252525252525252
Intangible assets, net ($M)($M)
10911645474849404142434445
Deferred tax assets, non-current ($M)($M)
82828181818181818181810
Other non-current assets ($M)($M)
618675605530546556594556641650766661
Accounts payable ($M)($M)
167161317267175226405373279183520494
Accrued liabilities ($M)($M)
1,9091,9121,3861,1789871,0011,4271,3761,3331,3961,7982,224
Deferred revenue, current ($M)($M)
295102991632181251533797025595681,372
Operating lease liabilities, current ($M)($M)
211917171615142125252533
Other current liabilities ($M)($M)
163220185731922522216942190129239
Total current liabilities ($M)($M)
2,5342,3951,9871,6811,5721,6042,2062,2012,3632,3803,0154,385
Operating lease liabilities, non-current ($M)($M)
638645653660666667671679668637643697
Deferred tax liabilities ($M)($M)
255253249239237234231241235
Other non-current liabilities ($M)($M)
284283285281276274267276266262256172
Total liabilities ($M)($M)
4,2004,0803,6882,8052,6112,6383,2413,8763,9683,9124,5725,995
Additional paid-in capital ($M)($M)
1,6441,5031,3821,2541,127982866751631487371277
Retained earnings (accumulated deficit) ($M)($M)
5,0985,8807,2238,0498,2499,07410,04511,16511,15212,43113,60613,389
Accumulated other comprehensive income (loss) ($M)($M)
192545272310-1011-71-101-123-211
Total stockholders' equity ($M)($M)
6,7617,4088,6509,3309,39910,06610,90111,92711,71212,81713,85413,455
Cash Flow Statement — Operating cash flow ($M)($M)10
-526-630930-847-919-1,037825-1,566-1,274-989622-1,600
Depreciation and amortization ($M)($M)
56566651563859514035203246
Stock-based compensation ($M)($M)
1201041131251301151041121121017977
Change in deferred revenue ($M)($M)
1905-674097-29-262-323179-33-887-194
Change in inventories ($M)($M)
-1326179-91-114-8291-11-104-93285228
Change in accounts receivable ($M)($M)
53114859-1,013302801,206-1,401-26755974-1,634
Change in accounts payable ($M)($M)
-8-1202289-47-1563496104-30321179
Capital expenditures ($M)($M)
376239333117522151182196220140
Net cash provided by (used in) investing activities ($M)($M)
329-76-48700564730-5397211,649118-538789
Net cash provided by (used in) financing activities ($M)($M)
1417581-194-3113414-109-58
Net increase (decrease) in cash, cash equivalents and restricted cash ($M)($M)
-185-6881,463-147-345-303282-833409-857-25-869

7 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Fiscal calendar & single-segment structure: Moderna, Inc. operates on a calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q1 2026 ended March 31, 2026; Q2 2026 ended June 30, 2026) and manages its business as a single global operating segment focused on mRNA medicines. Operational performance is therefore tracked through product-level vaccine sales, quarterly geographic net product sales, gross-to-net (GTN) reserve rollforwards, Cost of Sales manufacturing utilization drivers, clinical pipeline counts, R&D investment by therapeutic modality, and strategic co-development collaborations.
  • Core commercial, GTN & Cost of Sales KPIs (Groups 1–3) cover: (1) Commercial Respiratory Franchise & Geographic Net Product Sales ($1,831M in FY25 and $100M in Q2 2026 across COVID-19 vaccines Spikevax/mNEXSPIKE and RSV vaccine mRESVIA; 22 consecutive quarters of U.S., Europe, and Rest of World Net Product Sales disaggregation from Note 2 that are not in the standard segment database; U.S. retail pharmacy COVID-19 market share of 42% in FY25; 3 approved commercial products; and Stand-Ready Manufacturing revenue from sovereign mRNA facilities in the U.K., Canada, and Australia); (2) Gross-to-Net (GTN) Sales Reserves & APA Deferred Revenue ($3,262M gross product sales vs. -$1,431M GTN provisions in FY25, broken down into chargebacks/discounts and returns/rebates; $534M refund liability at Q2 2026; and $278M total deferred revenue across Advance Purchase Agreements and stand-ready contracts); and (3) Cost of Sales Drivers & Inventory by Stage ($868M Cost of Sales or 48% of net product sales in FY25, including $88M third-party royalties, $291M inventory write-downs, and $10M firm purchase commitment losses; $895M third-party royalties in Q1 2026 from the Arbutus/Genevant lipid nanoparticle litigation settlement; and $257M net inventory at Q2 2026 across Raw Materials, WIP, and Finished Goods).
  • Pipeline, R&D, Facilities, Capital & ESG KPIs (Groups 4–7) cover: (4) Clinical Pipeline & R&D by Modality (36 development programs across 26 development candidates at Q2 2026; 146 Moderna-sponsored clinical studies / 137 interventional trials / ~255,600 cumulative participants tracked via ClinicalTrials.gov API v2; $3,117M GAAP R&D in FY25 disaggregated into Infectious Disease Vaccines $652M, Oncology $201M, Rare Diseases $43M, Discovery & Platform Research $356M, Technical Development & Manufacturing $792M, and Shared Discovery & Development $797M; plus Merck mRNA-4157 50/50 R&D cost-sharing and Blackstone Life Sciences influenza funding); (5) Manufacturing Footprint, PP&E & Commitments ($2,250M net PP&E at Q2 2026 across U.S., Europe, and Rest of World; 769,000 sq ft in Cambridge and 679,000 sq ft at the Norwood manufacturing campus; $933M supply & manufacturing and $681M clinical service minimum purchase obligations at FY25); (6) Cash & Marketable Securities Portfolio ($3,537M amortized cost at Q2 2026 across U.S. Treasury debt, corporate debt, money market funds, and CDs; $398M SBC in FY25 across options, RSUs, PSUs, and ESPP; and $6,080M gross DTA offset by a $6,000M valuation allowance at FY25); and (7) Workforce, Quality & ESG (4,700 full-time employees across 18 countries in FY25, 119:1 CEO pay ratio, 14 health authority inspections with 100% acceptable outcomes and 0 recalls in FY25, Scope 1–3 GHG emissions, energy, water, waste, and 0.25 TRIR).
  • No parent-only standalone financial statements exist under U.S. GAAP (Form 10-K omits Schedule I), so no Consolidated − Standalone subtraction is performed. All values are strictly as published (with verbatim quotes on hover for text-extracted metrics). The only arithmetic shown in table cells is period splitting (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M), displayed in italic with the formula.

Không hiện vì thiếu các kỳ gần đây (11)

  • CDC / Our World in Data U.S. COVID-19 vaccine doses administered by manufacturer (Moderna vs. Pfizer): discontinued after May 2023 when the U.S. federal COVID-19 Public Health Emergency ended (fails the 3 recent continuous periods requirement).
  • Commercial vaccine doses delivered / shipped (millions of doses): Moderna disclosed full-year doses delivered only during the 2021–2022 pandemic APA period (~807M doses in FY2021) and discontinued periodic dose volume reporting from FY2023 onward.
  • Remaining Performance Obligations (RPO) / APA contract backlog ($B): disclosed intermittently in narrative notes (e.g., ~$4.2B in FY2025 10-K across multi-year horizons) without a consistent quarterly or annual point-in-time series across the last 3 quarters.
  • Clinical trial efficacy rates, seroconversion percentages, and geometric mean titer (GMT) ratios for individual pipeline candidates (mRNA-1283, mRNA-1010, mRNA-1083, mRNA-4157, mRNA-1647, mRNA-1403): event-specific clinical trial readouts rather than recurring periodic operational time series.
  • Scope 3 GHG emissions for FY2025: Moderna's 2025 Impacting Human Health Report published in April 2026 disclosed FY2021–FY2025 Scope 1 & 2 emissions, energy, water, and waste, while Scope 3 value-chain inventory is reported through FY2024 in the 2021–2024 Environmental Data table.
  • FRED CPI Prescription Drugs series (CUUR0000SEMF01): returned HTTP error / HTML from FRED endpoint; replaced with active FRED CPI Medical Care Commodities (CUSR0000SAM1) and PPI Pharmaceutical Preparation Manufacturing (PCU325412325412).
  • Approximate / bound-only disclosures ('more than 1,900 participants', 'over 1 billion doses', '>90% efficacy'): excluded per strict point-value rule (lib.quotes.is_bound).
  • Self-computed ratios, margins, YoY/QoQ growth percentages, and component sums not explicitly published by Moderna: excluded per strict derivation rule (only Q4 = FY - 9M and Q = YTD - prior YTD period splits are permitted).
  • Gross-to-Net (GTN) Sales Reserves, Customer Rebates & APA Deferred Revenue › Gross product sales (before gross-to-net variable consideration deductions) ($M) › Total gross-to-net (GTN) provisions & variable consideration deductions ($M) › GTN provision — Product returns, government rebates and refunds (legacy grouping) ($M)
  • Industry & Healthcare Benchmarks (FRED) & Core Financial Statements (Database Baseline) › Industry benchmarks (FRED) — U.S. PPI: Pharmaceutical Preparation Manufacturing (Index) › U.S. CPI: Medical Care Commodities / Medicinal Drugs (Index, 1982–84=100)
  • Industry & Healthcare Benchmarks (FRED) & Core Financial Statements (Database Baseline) › Industry benchmarks (FRED) — U.S. PPI: Pharmaceutical Preparation Manufacturing (Index) › U.S. CPI: Medical Care Services (Index, 1982–84=100)

Dữ liệu cập nhật 2026-11-03.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Cost of Sales Drivers, Manufacturing Utilization Charges & Inventory by Stage

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Moderna

See a number that looks wrong?